CD8 Reactivity to Microorganisms in Blood and Breast Milk
NCT03084614 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2019-11-14
Summary
Background:
When a person is exposed to something that causes an infection, the body sends a type of cell called CD8 T cells to attack it. Those cells are also found in breast milk. Nursing mothers pass these cells to their child, which helps the child fight infections, too. Researchers want to learn more about how CD8 cells work to keep people healthy.
Objective:
To learn more about how the human body fights off infections.
Eligibility:
People age 18 years and older who either have an infection, are suspected to have an infection, or recently got a vaccine.
The household contacts of these people and people who have not been recently exposed to any infection are also needed.
Design:
Participants will be screened with a medical and health history and physical exam. They may have blood tests.
The first study visit can be the same day as screening. It can be up to 3 months later. For those visits, screening tests will be repeated.
At the first visit, participants will have blood collected from an arm vein.
Participants who are breastfeeding may provide a small sample of breast milk. They may collect it at home or bring a pumping device to NIH to collect it. NIH can also provide a breast pump.
Participants may be contacted for up to 1 year after the first visit to give samples of blood and/or breast milk.
Up to 4 additional visits, which will each take about 1 hour, may be scheduled.
A personal physician or local lab can collect blood from participants and ship it to NIH. Breast milk cannot be shipped.
Conditions
- Immune Modulation
- Tuberculosis
- Leprosy
- Pertussis
- Lyme Disease
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Ian A Myles, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-28
- Primary Completion
- 2018-02-16
- Completion
- 2019-11-08
Countries
- United States
Study Locations
More Related Trials
-
Immune Cell Response to Stimuli
NCT00397280 ·Status: RECRUITING
-
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
NCT00085930 ·Status: COMPLETED ·Phase: PHASE1
-
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
NCT00867269 ·Status: RECRUITING
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
NCT04830046 ·Status: COMPLETED
-
In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients
NCT00001336 ·Status: COMPLETED
-
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582 ·Status: COMPLETED
-
Dendritic Cell Based Therapy of Metastatic Breast Cancer
NCT00197925 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
NCT06040918 ·Status: COMPLETED ·Phase: PHASE1
-
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT05325632 ·Status: RECRUITING ·Phase: PHASE2
-
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
NCT00622401 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer
NCT02018458 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
NCT00683670 ·Status: COMPLETED ·Phase: PHASE1
-
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
NCT03827343 ·Status: ACTIVE_NOT_RECRUITING
-
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors
NCT03114566 ·Status: TERMINATED
-
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
NCT05238792 ·Status: RECRUITING ·Phase: PHASE1
-
Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer
NCT00879489 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Biological Therapy in Treating Patients With Advanced Cancer
NCT00005956 ·Status: COMPLETED ·Phase: NA
-
Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
NCT04408950 ·Status: COMPLETED
-
Sequencing T-cells in Type I Diabetes Mellitus
NCT02040337 ·Status: COMPLETED
-
Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults
NCT00346619 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
NCT03630809 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma
NCT00430053 ·Status: COMPLETED
-
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
NCT04948619 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of Resistin on Neutrophil Function
NCT03626870 ·Status: WITHDRAWN